SkinHealth Systems Inc. (SKIN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SKIN SEC filings page.
SkinHealth Systems Inc. (SKIN) reported $290.0M in revenue over the twelve months to Jun 30, 2026, down 6.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is nearing operating break-even, but shrinking revenue and a much tighter liquidity structure still define its financing profile.
From FY2023 to FY2025, revenue fell to$300.8M while gross margin recovered to65.3% , indicating that improved unit economics came from cost or mix changes rather than sales scale. That recovery did not fully reach operating profit, which remained negative at$20.8M in FY2025.
FY2025 operating cash flow of
The balance sheet became substantially less flexible: the current ratio dropped from 7.0x in FY2024 to 1.7x in FY2025, while current liabilities rose to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of SkinHealth Systems Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
SkinHealth Systems Inc. has an operating margin of -6.9%, meaning the company loses $7 on every $100 of revenue. This results in a profitability score of 24/100. This is up from -20.3% the prior year.
SkinHealth Systems Inc.'s revenue declined 10.0% year-over-year, from $334.3M to $300.8M. This contraction results in a growth score of 7/100.
SkinHealth Systems Inc. has elevated debt relative to equity (D/E of 7.19), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 7/100, reflecting increased financial risk.
SkinHealth Systems Inc.'s current ratio of 1.66 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.
SkinHealth Systems Inc. has a free cash flow margin of 12.4%, earning a moderate score of 61/100. The company generates positive cash flow after capital investments, but with room for improvement.
SkinHealth Systems Inc. posts a -15.6% return on equity (ROE), meaning it loses $16 for every $100 of shareholders' equity. This results in a returns score of 26/100. This is up from -56.2% the prior year.
SkinHealth Systems Inc. scores -0.58, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($82.0M) relative to total liabilities ($438.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
SkinHealth Systems Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
SkinHealth Systems Inc. reported a net loss of $9.5M while generating $37.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
SkinHealth Systems Inc. reported an operating loss of $20.8M against $19.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
SkinHealth Systems Inc. generated $72.1M in revenue in Q2 2026. This represents a decrease of 7.8% from the same quarter a year earlier. Against the prior quarter it is up 11.1%.
SkinHealth Systems Inc.'s EBITDA was $7.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 366.3% from the same quarter a year earlier. Against the prior quarter it is up 228.0%.
SkinHealth Systems Inc. reported -$2.7M in net income in Q2 2026. This represents a decrease of 113.5% from the same quarter a year earlier. Against the prior quarter it is up 59.7%.
SkinHealth Systems Inc. earned -$0.02 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 60.0%.
Cash & Balance Sheet
SkinHealth Systems Inc. generated $2.2M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 76.5% from the same quarter a year earlier. Against the prior quarter it is up 138.8%.
SkinHealth Systems Inc. held $206.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
SkinHealth Systems Inc.'s gross margin was 68.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.6 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
SkinHealth Systems Inc.'s operating margin was 5.0% in Q2 2026, reflecting core business profitability. This is up 8.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.7 percentage points.
SkinHealth Systems Inc.'s net profit margin was -3.7% in Q2 2026, showing the share of revenue converted to profit. This is down 28.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.5 percentage points.
SkinHealth Systems Inc.'s ROE was -4.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 31.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.2 percentage points.
Capital Allocation
SkinHealth Systems Inc. invested $1.4M in research and development in Q2 2026. This represents an increase of 12.5% from the same quarter a year earlier. Against the prior quarter it is up 27.7%.
SkinHealth Systems Inc. invested $427K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 364.1% from the same quarter a year earlier. Against the prior quarter it is up 90.6%.
Not reported for Q2 2026.
SKIN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.1M-7.8% | $64.9M-6.7% | $82.4M-1.3% | $70.7M-10.3% | $78.2M-13.7% | $69.6M-14.5% | $83.5M-13.8% | $78.8M-19.1% |
| Cost of Revenue | $22.8M-21.7% | $20.5M-2.5% | $29.3M-5.8% | $25.0M-34.4% | $29.1M-41.4% | $21.0M-36.4% | $31.1M-39.1% | $38.2M-65.3% |
| Gross Profit | $49.3M+0.5% | $44.4M-8.5% | $53.0M+1.3% | $45.6M+12.3% | $49.1M+20.0% | $48.6M+0.5% | $52.3M+14.6% | $40.6M+423.8% |
| R&D Expenses | $1.4M+12.5% | $1.1M+10.4% | $1.7M+37.6% | $1.7M+53.2% | $1.3M+7.9% | $998K-64.4% | $1.2M-59.9% | $1.1M-39.7% |
| SG&A Expenses | $23.3M-15.0% | $21.9M-34.6% | $27.7M-12.8% | $29.3M-12.5% | $27.5M-12.6% | $33.6M+16.3% | $31.8M+9.6% | $33.4M-9.6% |
| Operating Income | $3.6M+232.3% | -$1.8M+85.0% | $162K+102.3% | -$6.2M+71.0% | -$2.7M+87.8% | -$12.0M+29.2% | -$7.2M+61.0% | -$21.5M+73.8% |
| EBITDA | $7.6M+366.3% | $2.3M+133.2% | $4.3M+389.3% | $1.1M+108.3% | $1.6M+111.5% | -$7.0M+24.3% | -$1.5M+83.7% | -$13.4M+82.1% |
| Interest Expense | $6.3M+51.9% | $6.3M+154.0% | $6.4M+158.7% | $6.3M+155.7% | $4.1M+69.0% | $2.5M-17.5% | $2.5M-26.7% | $2.5M-28.4% |
| Income Tax | $1.2M+221.7% | -$184K-120.6% | $3.3M+337.5% | $386K-80.2% | -$993K-181.3% | $892K+235.4% | -$1.4M-330.2% | $1.9M-44.0% |
| Net Income | -$2.7M-113.5% | -$6.6M+34.3% | -$8.1M+21.7% | -$11.0M+39.7% | $19.7M+9658.4% | -$10.1M-1386.9% | -$10.3M-10.1% | -$18.3M+75.2% |
| EPS (Basic) | -$0.02-112.5% | -$0.05+37.5% | -$0.07+12.5% | -$0.09+40.0% | $0.16 | -$0.08-700.0% | -$0.080.0% | -$0.15+73.2% |
| EPS (Diluted) | -$0.02 | -$0.05+37.5% | -$0.050.0% | -$0.09+40.0% | $0.03+130.0% | -$0.08 | -$0.05 | -$0.15+73.2% |
| Diluted Shares (Avg) | 130M | 131M+5.1% | N/A | 127M+2.3% | 140M-1.2% | 125M | N/A | 124M-6.7% |
SKIN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $486.6M-4.1% | $473.2M-29.8% | $499.8M-27.1% | $503.6M-28.0% | $507.6M-28.7% | $673.8M-20.2% | $685.7M-26.2% | $699.5M-28.1% |
| Current Assets | $295.2M-3.5% | $277.7M-40.8% | $309.5M-35.1% | $308.4M-36.4% | $306.1M-37.5% | $469.4M-23.7% | $477.1M-31.7% | $485.0M-34.3% |
| Cash & Equivalents | $206.1M-2.8% | $204.4M-45.2% | $232.7M-37.1% | $219.4M-38.9% | $212.0M-39.3% | $373.0M-16.1% | $370.1M-29.2% | $358.9M-35.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $46.8M-20.9% | $47.7M-27.3% | $48.0M-30.5% | $56.1M-23.6% | $59.2M-23.3% | $65.6M-31.4% | $69.1M-24.3% | $73.4M-1.9% |
| Accounts Receivable | $17.6M-29.6% | $18.6M-20.0% | $21.7M-21.4% | $22.2M-38.8% | $25.0M-39.5% | $23.3M-51.2% | $27.6M-49.5% | $36.3M-45.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $126.3M+0.1% | $126.2M+1.6% | $126.6M+2.5% | $126.5M+0.8% | $126.3M+1.2% | $124.3M-0.9% | $123.5M-1.8% | $125.5M+0.6% |
| Total Liabilities | $431.0M-0.6% | $418.0M-33.4% | $438.7M-30.8% | $438.0M-31.5% | $433.6M-32.5% | $627.8M-19.7% | $633.9M-27.1% | $639.8M-27.5% |
| Current Liabilities | $168.2M+183.0% | $155.2M+147.1% | $186.3M+173.3% | $61.9M-16.3% | $59.4M-21.2% | $62.8M-32.9% | $68.2M-40.7% | $73.9M-41.3% |
| Non-Current Liabilities | $262.8M-29.8% | $262.8M-53.5% | $252.5M-55.4% | $376.1M-33.5% | $374.1M-34.0% | $565.0M-17.9% | $565.7M-25.0% | $565.9M-25.3% |
| Long-Term Debt | N/A | N/A | N/A | $363.4M | $363.1M | N/A | $552.2M | N/A |
| Total Equity | $55.6M-24.9% | $55.2M+19.9% | $61.1M+17.9% | $65.7M+9.9% | $74.0M+7.0% | $46.1M-27.2% | $51.8M-12.8% | $59.7M-33.6% |
| Retained Earnings | -$526.8M-5.7% | -$524.1M-1.2% | -$517.5M-1.9% | -$509.4M-2.4% | -$498.3M-4.0% | -$518.1M-8.0% | -$508.0M-6.1% | -$497.6M-6.0% |
SKIN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.7M-72.3% | -$5.6M-285.4% | $15.2M-7.7% | $9.6M-6.5% | $9.6M+55.6% | $3.0M+117.8% | $16.5M+418.6% | $10.3M-42.6% |
| Depreciation & Amortization | $4.0M-6.8% | $4.1M-18.2% | $4.1M-27.4% | $7.3M-9.4% | $4.3M-45.4% | $5.0M-35.1% | $5.7M-38.9% | $8.1M+10.5% |
| Stock-Based Compensation | $2.9M-45.5% | $2.1M-40.2% | N/A | $2.5M-68.2% | $5.3M-18.3% | $3.5M-47.6% | N/A | $7.7M-5.8% |
| Capital Expenditures | $427K+364.1% | $224K+397.8% | $139K+87.8% | $27K+575.0% | $92K-72.5% | $45K-86.9% | $74K+164.3% | $4K-97.7% |
| Free Cash Flow | $2.2M-76.5% | -$5.8M-295.8% | $15.1M-8.2% | $9.6M-6.7% | $9.6M+62.8% | $3.0M+117.2% | $16.4M+415.5% | $10.3M-42.0% |
| Investing Cash Flow | -$1.2M+22.4% | -$1.6M-44.0% | -$1.4M-60.3% | -$1.1M+48.2% | -$1.6M+23.8% | -$1.1M+36.5% | -$862K+60.2% | -$2.1M+52.8% |
| Financing Cash Flow | -$224K+99.9% | -$20.9M-8262.4% | -$512K+33.5% | -$803K-293.6% | -$173.4M-75.6% | -$250K+99.6% | -$770K+97.5% | -$204K+91.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SKIN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 68.4%+5.6pp | 68.5%-1.4pp | 64.4%+1.7pp | 64.6%+13.0pp | 62.8%+17.6pp | 69.8%+10.4pp | 62.7%+15.5pp | 51.6%+64.5pp |
| Operating Margin | 5.0%+8.4pp | -2.8%+14.5pp | 0.2%+8.8pp | -8.8%+18.5pp | -3.5%+21.0pp | -17.3%+3.6pp | -8.6%+10.4pp | -27.3%+57.0pp |
| Net Margin | -3.7%-28.9pp | -10.2%+4.3pp | -9.8%+2.6pp | -15.6%+7.6pp | 25.2%+25.0pp | -14.5%-13.7pp | -12.4%-2.7pp | -23.2%+52.6pp |
| Return on Equity | -4.8%-31.4pp | -12.0%+9.9pp | -13.2%+6.7pp | -16.8%+13.8pp | 26.6%+26.4pp | -21.9%-20.9pp | -19.9%-4.1pp | -30.6%+51.4pp |
| Return on Assets | -0.5%-4.4pp | -1.4%+0.1pp | -1.6%-0.1pp | -2.2%+0.4pp | 3.9%+3.9pp | -1.5%-1.4pp | -1.5%-0.5pp | -2.6%+5.0pp |
| Current Ratio | 1.76-3.4x | 1.79-5.7x | 1.66-5.3x | 4.98-1.6x | 5.15-1.3x | 7.47+0.9x | 7.00+0.9x | 6.56+0.7x |
| Debt-to-Equity | 7.76+2.8x | 7.57-6.1x | 7.19-3.5x | 5.53-5.2x | 4.91-4.4x | 13.63+1.3x | 10.66-4.0x | 10.71+0.9x |
| Asset Turnover | 0.150.0x | 0.140.0x | 0.160.0x | 0.140.0x | 0.150.0x | 0.100.0x | 0.120.0x | 0.110.0x |
| FCF Margin | 3.1%-9.1pp | -8.9%-13.1pp | 18.3%-1.4pp | 13.6%+0.5pp | 12.2%+5.7pp | 4.2%+25.4pp | 19.6%+25.0pp | 13.1%-5.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| SkinHealth Systems Inc. SKIN | FY2025 | $300.8M | -$9.5M | -3.2% | $82.0M | 29/100 |
| Helen Of Troy Ltd HELE | FY2026 | $1.8B | -$899.0M | -50.3% | $622.8M | 32/100 |
| The Honest Company, Inc. HNST | FY2025 | $371.3M | -$15.7M | -4.2% | $553.6M | 49/100 |
| NuSkin Enterprises, Inc. NUS | FY2025 | $1.5B | $160.2M | 10.8% | $224.4M | 40/100 |
| Yatsen Holding Limited YSG | FY2025 | $614.6M | -$11.6M | -1.9% | $247.6M | 50/100 |
| Edgewell Personal Care Company EPC | FY2025 | $2.2B | $25.4M | 1.1% | $1.2B | 37/100 |
Where SkinHealth Systems Inc. Ranks
Frequently Asked Questions
What is SkinHealth Systems Inc.'s annual revenue?
SkinHealth Systems Inc. (SKIN) reported $300.8M in total revenue for fiscal year 2025. This represents a -10.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is SkinHealth Systems Inc.'s revenue growing?
SkinHealth Systems Inc. (SKIN) revenue declined by 10.0% year-over-year, from $334.3M to $300.8M in fiscal year 2025.
Is SkinHealth Systems Inc. profitable?
No, SkinHealth Systems Inc. (SKIN) reported a net income of -$9.5M in fiscal year 2025, with a net profit margin of -3.2%.
What is SkinHealth Systems Inc.'s EBITDA?
SkinHealth Systems Inc. (SKIN) had EBITDA of $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is SkinHealth Systems Inc.'s gross margin?
SkinHealth Systems Inc. (SKIN) had a gross margin of 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is SkinHealth Systems Inc.'s operating margin?
SkinHealth Systems Inc. (SKIN) had an operating margin of -6.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is SkinHealth Systems Inc.'s net profit margin?
SkinHealth Systems Inc. (SKIN) had a net profit margin of -3.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is SkinHealth Systems Inc.'s return on equity (ROE)?
SkinHealth Systems Inc. (SKIN) has a return on equity of -15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is SkinHealth Systems Inc.'s free cash flow?
SkinHealth Systems Inc. (SKIN) generated $37.2M in free cash flow during fiscal year 2025. This represents a 141.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is SkinHealth Systems Inc.'s operating cash flow?
SkinHealth Systems Inc. (SKIN) generated $37.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are SkinHealth Systems Inc.'s total assets?
SkinHealth Systems Inc. (SKIN) had $499.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are SkinHealth Systems Inc.'s capital expenditures?
SkinHealth Systems Inc. (SKIN) invested $303K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does SkinHealth Systems Inc. spend on research and development?
SkinHealth Systems Inc. (SKIN) invested $5.6M in research and development during fiscal year 2025.
What is SkinHealth Systems Inc.'s current ratio?
SkinHealth Systems Inc. (SKIN) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.
What is SkinHealth Systems Inc.'s debt-to-equity ratio?
SkinHealth Systems Inc. (SKIN) had a debt-to-equity ratio of 7.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is SkinHealth Systems Inc.'s return on assets (ROA)?
SkinHealth Systems Inc. (SKIN) had a return on assets of -1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is SkinHealth Systems Inc.'s P/E ratio?
SkinHealth Systems Inc. (SKIN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $82.0M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is SkinHealth Systems Inc.'s price-to-sales ratio?
SkinHealth Systems Inc. (SKIN) trades at 0.3x sales, its market capitalization divided by revenue of $290.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $82.0M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is SkinHealth Systems Inc.'s Altman Z-Score?
SkinHealth Systems Inc. (SKIN) has an Altman Z-Score of -0.58, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is SkinHealth Systems Inc.'s Piotroski F-Score?
SkinHealth Systems Inc. (SKIN) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are SkinHealth Systems Inc.'s earnings high quality?
SkinHealth Systems Inc. (SKIN) reported a net loss of $9.5M while generating $37.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can SkinHealth Systems Inc. cover its interest payments?
SkinHealth Systems Inc. (SKIN) reported an operating loss of $20.8M against $19.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is SkinHealth Systems Inc.?
SkinHealth Systems Inc. (SKIN) scores 29 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.